What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?
There is evidence that treatment can decrease the risk of fractures in osteoporotic patients, and screening of these patients is therefore relevant. Diagnosis of osteoporosis is based on the T-score calculated from bone mineral density (BMD) measurements. BMD measurements have been widely used for the management of osteoporosis, and a low BMD is a strong risk factor for fractures. But BMD measurement has several limitations in both diagnosis, prediction of fracture risk, and treatment follow-up. Quantitative ultrasound (QUS) parameters, an alternative to BMD in the assessment of bone, are independent risk factors for osteoporotic fracture. However, the use of QUS cannot be recommended for both allocation and monitoring of treatment. Biochemical markers of bone remodelling can be useful for both prediction of fracture risk and monitoring of treatment if sources of variability are controlled.
Briot
Karine
K
Département de Rhumatologie, Hôpital Cochin, 27 Rue du Faubourg St Jacques, 75014 Paris, France.
Roux
Christian
C
D015502:Absorptiometry, Photon; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000502:physiology*; D016723:Bone Remodeling; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D010347:Patient Care Planning; D011237:Predictive Value of Tests; D012307:Risk Factors; D014463:Ultrasonography
D015415:Biomarkers